Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 246 clinical trials
  • None views
  • None views
  • None views
  • None views
  • None views
  • None views
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging

Known risk factors inducing squamous cell carcinomas of the head and neck are tabacco and alcohol intake. However, the incidence of human papillomavirus (HPV) related oropharyngeal carcinomas is increasing. It is known that HPV+ and HPV- tumors have a different reaction to (chemo)radiotherapy.

ct scan
chemoradiotherapy
squamous cell carcinoma of the head and neck
oropharyngeal carcinoma
immunohistochemistry
  • 0 views
  • 16 Feb, 2024
  • 1 location
INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

This is an open-label phase1/2, multi-center trial to evaluate the efficacy, safety, tolerability and immunogenicity of INO-3107 in participants with HPV-6 and/or HPV-11 associated recurrent respiratory papillomatosis (RRP). The trial population is divided into two cohorts: Cohort A: Participants with diagnoses of Juvenile-Onset RRP as defined by age at first …

recurrent respiratory papillomatosis
papillomatosis
respiratory papilloma
renal function
vasectomy
  • 0 views
  • 05 Aug, 2020
Optimising Radiation Therapy in Head and Neck Cancers Using Functional Image-Guided Radiotherapy and Novel Biomarkers

Cohort 1: HPV-associated OPC consisting of 25 participants Cohort 2: HPV-negative OPC consisting of a minimum of 10 patients and a maximum of 53 participants Cohort 3: Base of Skull HNC consisting of 25 participants

chemoradiotherapy
neck cancer
induction chemotherapy
squamous cell carcinoma of head and neck
head and neck cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Evaluate the Efficacy Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .

intrauterine device (iud)
recombinant vaccine
flushed skin
gardasil
human papillomavirus
  • 0 views
  • 16 Feb, 2024
  • 1 location